-

11:05:41 AM

TPST Stock News

TPST - Tempest Therapeutics Inc

05/31/23 4:05 PM

Nasdaq : TPST

conferenceslow float

Tempest to Present at the Jefferies Global Healthcare Conference

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Global

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : TPST

conferencesclinical triallow float

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety profile • Data to be reported at the 2023 ASCO Annual Meeting BRISBANE, Calif., May 25, 2023 (GLOBE

RHEA-AI

neutral

05/19/23 4:05 PM

Nasdaq : TPST

low float

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the company’s

RHEA-AI

very positive

05/10/23 4:15 PM

Nasdaq : TPST

earningslow float

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023

RHEA-AI

neutral

04/28/23 8:00 AM

Nasdaq : TPST

clinical triallow float

Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumab The addition of TPST-1120 resulted in a clinically-meaningful improvement in both confirmed and unconfirmed RECIST responses The number of patients on treatment and

RHEA-AI

neutral

04/27/23 4:58 PM

Nasdaq : TPST

conferencesclinical triallow float

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms,

RHEA-AI

neutral

04/26/23 6:41 PM

Nasdaq : TPST

low float

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a

RHEA-AI

neutral

04/17/23 9:00 AM

Nasdaq : TPST

clinical triallow float

Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that new data from its TPST-1120 and TREX1 programs

RHEA-AI

neutral

03/22/23 5:26 PM

Nasdaq : TPST

earningslow float

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Positive monotherapy and combination therapy data from Phase 1 trial of first clinical program, TPST-1120, announced in an oral presentation at ASCO 2022 TPST-1120 randomized combination study in first-line HCC patients with partner Roche is fully enrolled, with initial data expected in the first

RHEA-AI

neutral

03/15/23 4:05 PM

Nasdaq : TPST

conferenceslow float

Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Nathan Standifer Ph.D., Executive Director of

RHEA-AI

neutral

TPST Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.tempesttx.com
CeoJulia Owens
Security nameTempest Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Address110 Miller Ave Ste 100
StateMichigan
CityAnn Arbor
Zip48104-1305
CountryUS
Phone17348459000

About Tempest Therapeutics Inc

Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARa, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally available inhibitor of TREX-1 designed to activate the cGAS/STING pathway selectively. Tempest is headquartered in South San Francisco and supported by notable healthcare investors.